THIRD QUARTER IN BRIEF
- Based on the authorization from the general meeting, the board of directors resolved to carry out a rights issue of approximately
SEK 55 million to secure financing of the ongoing and planned development programs (Aug 4 ) - The first part of the multiple dose of laquinimod eye drops in the phase I study has been completed without any serious side effects that can be linked to laquinimod and the study has been expanded with another dose group
Active Biotech announces final outcome of the company’s rights issue (Sep 7 )
EVENTS AFTER THE END OF THE PERIOD
Active Biotech further strengthens the patent protection for laquinimod in eye disorders with a granted patent in US (Oct 24 )
Financial summary
SEK M | Jul-Sep | Jan-Sep | Full year | ||
2022 2021 | 2022 2021 | 2021 | |||
Net sales | - | - | - | - | - |
Operating profit/loss | -13,4 | -11,3 | -42,6 | -33,6 | -49,8 |
Profit/loss after tax | -13,4 | -11,2 | -43,4 | -33,7 | -49,8 |
Earnings per share (SEK) | -0,06 | -0,05 | -0,19 | -0,16 | -0,24 |
Cash and cash equivalents (at close of period) | 55,0 | 68,4 | 53,1 |
The report is also available at www.activebiotech.com.
© Modular Finance, source